Yükleniyor... / Loading...
This study examines the relationship between BRCA1 gene expression and chemotherapy response in patients with metastatic gastric cancer. It included patients with metastatic gastric adenocarcinoma who had at least one measurable lesion and an ECOG performance status of 0-2. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Metastatic gastric cancer( Adenocarcinoma) * Eastern Cooperative Oncology Group (ECOG) performance 0-2 * one more measure lesion * White blood cell count (WBC) \> 3000/ul , Platelet \> 75,000/ul * Normal kidney function (serum creatinine \< 1.5 ULN) * Normal Liver function (Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) \< 3 times of upper normal limit, if liver metastasis, AST/ALT \< 5 times of upper normal limit) * life expectancy is more than 3 months * Conventional surgery that does not cause the transformation of the target lesion is allowed * The patient who voluntarily decided to participate in this study and agreed in writing Exclusion Criteria: * Her-2 positive advanced gastric cancer * Central nervous system metastases requiring treatment with symptoms * Major uncontrolled cardiovascular disease (including myocardial infarction and congestive heart failure within 6 months) * Uncontrolled infection or other serious diseases * Patients with serious medical conditions or serious illnesses * Patient who is pregnant or lactating * Adjuvant chemotherapy before 6 months (patients who have not received platinum-based chemotherapy even if they are 6 months old can register) * In the past, if the primary lesion or target lesion was treated with radiation (if the recurred lesion is outside the range of radiation therapy)